Information on this page is intended for Ireland healthcare professionals only and may contain promotional material
This page is only intended for Irish healthcare professionals.
Adverse event reporting can be found near the bottom of the webpage. Click the bottom right button for Prescribing Information.
Mechanism Of Action
How does Dificlir work?
Treatment with antibacterial agents can deplete the commensal bacteria that normally colonise the colon.1-3
When this happens, C. difficile bacteria can multiply and produce toxins which cause illness such as diarrhoea and fever. At this point, a person is said to be infected with C. difficile.3
Dificlir is an antibiotic that belongs to the class of macrocylic antibiotics. When it is swallowed most of the active substance does not get absorbed into the blood stream but acts locally on C. difficile bacteria in the gut.4
It works by blocking the bacterial enzyme RNA polymerase, which is used to produce the genetic material that the bacteria need to make proteins.5 This stops the C. difficile bacteria from growing and multiplying, thereby reducing the symptoms of the disease.5
Dificlir is available in tablets and granules:
Dificlir 200mg film-coated tablets: are indicated for the treatment of Clostridioides difficile infections (CDI), also known as C. difficile-associated diarrhoea (CDAD), in adult and paediatric patients with a body weight of at least 12.5 kg.6
Dificlir 40mg/ml granules for oral suspension: is indicated for the treatment of Clostridioides difficile infections (CDI) also known as C. difficile-associated diarrhoea (CDAD) in adults and paediatric patients from birth to <18 years of age.
Consideration should be given to official guidelines on the appropriate use of antibacterial agents.7
Report a side effect
Adverse events should be reported. Reporting forms and information can be found at:
https://www.hpra.ie/report-an-issue/medicines-for-human-use/side-effects
Adverse events should also be reported to Tillotts Pharma UK Ltd on:
Tel: +353 1 2942015
Email: Pvireland@tillotts.com
References
1. Louie TJ, Cannon K, Byrne B et al.(2012) Fidaxomicin Preserves the Intestinal Microbiome During and After Treatment of Clostridium difficile Infection (CDI) and Reduces Both Toxin Reexpression and Recurrence of CDI; 55(S2): 132–142
2. Meehan et al.(2016) Challenges in management of recurrent and refractory Clostridium difficile infection. World J Clin Infect Dis; 6: 28-36
3. McFarland LV. (2005) Alternative treatments for Clostridium difficile disease: what really works? J Med Microbiol; 54: 101-11.
4. Cole and Stahl.(2015) Persistent and recurrent Clostridium difficile colitis. Clin Colon Rectal Surg; 28: 65-69
5. Mullane KM, Gorbach S.(2011) Fidaxomicin: first-in-class macrocyclic antibiotic. Expert Rev Anti Infect Ther; 9: 767-777
6. DIFICLIR™ 200 mg film-coated tablets SmPC.
7. DIFICLIR™ 40 mg/ml granules for oral suspension SmPC.
PM-DIF200-IE-00016 | October 2025
